Guangdong Hybribio Biotech Co Ltd (300639) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.018x

Based on the latest financial reports, Guangdong Hybribio Biotech Co Ltd (300639) has a cash flow conversion efficiency ratio of 0.018x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥66.39 Million ≈ $9.71 Million USD) by net assets (CN¥3.73 Billion ≈ $545.62 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check 300639 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Guangdong Hybribio Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2025)

This chart illustrates how Guangdong Hybribio Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. See Guangdong Hybribio Biotech Co Ltd (300639) net assets for net asset value and shareholders' equity analysis.

Guangdong Hybribio Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Guangdong Hybribio Biotech Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Zhongtong Guomai Communication SHG:603559	-0.159x
Mühlbauer Holding AG XETRA:MUB	0.114x
Mattr Corp TO:MATR	0.106x
American Woodmark Corporation NASDAQ:AMWD	-0.015x
Rainbow Tours SA WAR:RBW	0.323x
DXN HOLDINGS BHD. KLSE:5318	0.041x
Mnc Land Tbk JK:KPIG	0.018x
Ningbo Tianlong Electronics Co Ltd SHG:603266	0.008x

Annual Cash Flow Conversion Efficiency for Guangdong Hybribio Biotech Co Ltd (2012–2025)

The table below shows the annual cash flow conversion efficiency of Guangdong Hybribio Biotech Co Ltd from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see 300639 company net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥3.66 Billion ≈ $535.84 Million	CN¥341.61 Million ≈ $49.99 Million	0.093x	+379.19%
2024-12-31	CN¥4.05 Billion ≈ $592.14 Million	CN¥78.78 Million ≈ $11.53 Million	0.019x	-68.94%
2023-12-31	CN¥5.10 Billion ≈ $746.11 Million	CN¥319.60 Million ≈ $46.77 Million	0.063x	-74.98%
2022-12-31	CN¥5.23 Billion ≈ $764.86 Million	CN¥1.31 Billion ≈ $191.58 Million	0.250x	+37.87%
2021-12-31	CN¥3.48 Billion ≈ $508.50 Million	CN¥631.34 Million ≈ $92.39 Million	0.182x	+47.91%
2020-12-31	CN¥2.53 Billion ≈ $370.84 Million	CN¥311.30 Million ≈ $45.55 Million	0.123x	+28.97%
2019-12-31	CN¥1.18 Billion ≈ $173.35 Million	CN¥112.83 Million ≈ $16.51 Million	0.095x	+27.97%
2018-12-31	CN¥1.08 Billion ≈ $158.05 Million	CN¥80.39 Million ≈ $11.76 Million	0.074x	-8.72%
2017-12-31	CN¥970.90 Million ≈ $142.07 Million	CN¥79.17 Million ≈ $11.58 Million	0.082x	-35.72%
2016-12-31	CN¥501.67 Million ≈ $73.41 Million	CN¥63.63 Million ≈ $9.31 Million	0.127x	+8.26%
2015-12-31	CN¥413.71 Million ≈ $60.54 Million	CN¥48.47 Million ≈ $7.09 Million	0.117x	+16.51%
2014-12-31	CN¥344.60 Million ≈ $50.43 Million	CN¥34.65 Million ≈ $5.07 Million	0.101x	-15.93%
2013-12-31	CN¥191.38 Million ≈ $28.01 Million	CN¥22.89 Million ≈ $3.35 Million	0.120x	-3.12%
2012-12-31	CN¥130.29 Million ≈ $19.06 Million	CN¥16.08 Million ≈ $2.35 Million	0.123x	--

About Guangdong Hybribio Biotech Co Ltd

SHE:300639 China Diagnostics & Research

Market Cap

$561.94 Million

CN¥3.84 Billion CNY

Market Cap Rank

#11919 Global

#3533 in China

Share Price

CN¥5.94

Change (1 day)

-3.57%

52-Week Range

CN¥5.38 - CN¥8.81

All Time High

CN¥19.74